AstraZeneca, the Anglo-Swedish pharmaceutical giant, has recently launched a new health-tech business called Evinova. This venture will leverage the company’s expertise in clinical trial design and study delivery to offer solutions at scale to trial sponsors, clinical research organizations, care teams, and patients.

Evinova’s offerings will include advanced data collection methods and machine learning algorithms to support study design teams. The goal is to reduce the time and cost of developing new medicines, bring care closer to home for patients, and ease the burden on healthcare systems. The company has announced major collaborations with clinical research organizations Parexel and Fortrea to expand the reach of Evinova’s digital health solutions to a wider customer base.

AstraZeneca’s Chief Executive, Pascal Soriot, expressed confidence in Evinova’s potential to make a significant impact on patient care, healthcare transformation, and carbon emissions reduction. The company also highlighted the expected growth of the digital health market, projecting it to be worth more than $900 billion by 2032.

For more information about Evinova or AstraZeneca’s digital health solutions, contact Michael Susin at michael.susin@wsj.com.